Development of alkylating agent-resistant human tumor cell lines

Area of Science:

• Pharmacology and Toxicology
• Cancer Cell Biology
• Chemotherapy Research

Background:

• Alkylating agents are a cornerstone of cancer chemotherapy.
• Tumor cell lines exhibit differential sensitivity to chemotherapeutic drugs.
• Understanding inter-cell line variability is key to optimizing treatment.

Purpose of the Study:

• To evaluate the dose-response relationships of four human tumor cell lines to various alkylating agents.
• To compare the sensitivity and tolerance of different cell lines (SL6, SW2, SCC-25, G3361) to HN2, CDDP, 4-HC, L-PAM, and BCNU.
• To identify patterns of drug resistance and sensitivity among these representative cancer models.

Main Methods:

• Survival curves were generated for four human tumor cell lines.
• Dose escalation studies were performed using HN2, CDDP, 4-HC, L-PAM, and BCNU.
• Quantification of drug concentration required for specific log cell kill and maximal tolerated concentrations were determined.

Main Results:

• Significant variability in drug concentration for one log cell kill was observed across cell lines for all agents tested (e.g., HN2: 4.5 microM for SL6 vs. 22 microM for SW2).
• SCC-25 cells demonstrated the lowest tolerance to increasing concentrations of alkylating agents, while SL6 and G3361 cells exhibited the greatest tolerance.
• Specific examples include: 100 microM CDDP killed 4 logs of SCC-25 cells, but only 1 log of SL6 cells; SCC-25 tolerated 600 microM CDDP, while G3361 tolerated 1900 microM.

Conclusions:

• Human tumor cell lines display marked heterogeneity in their response to alkylating agents.
• The SCC-25 cell line is consistently more sensitive and less tolerant to these chemotherapeutics compared to SL6 and G3361.
• These differential responses underscore the importance of considering individual tumor cell characteristics in the development of targeted chemotherapy regimens.